Myriad Genetics (MYGN) Operating Leases (2019 - 2025)
Historic Operating Leases for Myriad Genetics (MYGN) over the last 7 years, with Q3 2025 value amounting to $84.9 million.
- Myriad Genetics' Operating Leases fell 629.14% to $84.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.9 million, marking a year-over-year decrease of 629.14%. This contributed to the annual value of $87.9 million for FY2024, which is 975.36% down from last year.
- According to the latest figures from Q3 2025, Myriad Genetics' Operating Leases is $84.9 million, which was down 629.14% from $86.2 million recorded in Q2 2025.
- Over the past 5 years, Myriad Genetics' Operating Leases peaked at $130.9 million during Q4 2022, and registered a low of $5.9 million during Q1 2023.
- Its 5-year average for Operating Leases is $76.3 million, with a median of $86.2 million in 2025.
- In the last 5 years, Myriad Genetics' Operating Leases crashed by 9521.49% in 2023 and then soared by 149830.51% in 2024.
- Myriad Genetics' Operating Leases (Quarter) stood at $79.3 million in 2021, then surged by 65.07% to $130.9 million in 2022, then fell by 25.59% to $97.4 million in 2023, then fell by 9.75% to $87.9 million in 2024, then decreased by 3.41% to $84.9 million in 2025.
- Its last three reported values are $84.9 million in Q3 2025, $86.2 million for Q2 2025, and $87.4 million during Q1 2025.